Supernus Pharma (SUPN) Tops Q3 EPS by 25c, updates guidance

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.69, $0.25 better than the analyst estimate of $0.44. Revenue for the quarter came in at $175.69 million versus the consensus estimate of $157.3 million.

GUIDANCE:

Supernus Pharma sees FY2024 revenue of $630-650 million, versus the consensus of $619.5 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Colgate-Palmolive explores sale of Softsoap, Irish Spring brands
• Cosmos Health unit secures 2.5M-unit drug manufacturing deal with Viofar
• Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance